Covidien Completes $100 Million CNS Therapeutics Deal

NEW YORK (AP) — Drug and medical device maker Covidien (NYSE: COV  ) said Tuesday it completed its $100 million purchase of CNS Therapeutics.

CNS makes gablofen, a generic version of a drug that treats severe spasticity, and it is developing other pain and spasticity treatments. Covidien announced it was buying CNS on Sept. 24.

CNS is now part of Covidien's Mallinckrodt pharmaceuticals business. The Irish drugmaker plans to spin off Mallinckrodt into a separate publicly traded company in mid-2013.

Shares of Covidien rose 13 cents to close at $59.41.

The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Covidien Ltd.. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2040973, ~/Articles/ArticleHandler.aspx, 9/18/2014 9:48:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement